Our publications

Standardising terminology in routine electronic health records for respiratory endpoints: why we still can’t agree.

Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.

Many essential inhaled medicines recommended in guidelines are delivered to the lung via pressurized metered-dose inhalers (pMDIs). Global...

How do acute worsening events influence daily life and healthcare-seeking behaviour in patients with COPD: an international multicountry qualitative study.

To explore the impact of acute worsening events (AWEs), defined as clinically relevant deteriorations in peak expiratory flow, reliever use and/or...

The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care.

Bronchiectasis is a common chronic respiratory disease with rising prevalence, hospitalisation rates, and mortality. It is estimated to affect...

Reply to “Stepping up ICS doses in asthma: the crucial roles of relievers, triple therapy, and biomarkers” and “Methodological challenges in evaluating high-dose ICS escalation”.

Consistency Between Oscillometry and Spirometry in Patients with Suspected or Confirmed COPD or Asthma: Results from a Multi-Center Study in China.

Spirometry is the standard for assessing airflow obstruction but can be challenging and/or time-consuming for patients. Oscillometry offers an...

Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study.

Cardiovascular diseases are prevalent in individuals with chronic obstructive pulmonary disease (COPD), but current cardiovascular risk assessment...

Nasal Airway Transcriptome Reflects Selected Asthma-Associated Gene Signatures in the Lower Airways.

Transcriptomic analysis of bronchial brushes reveals asthma-associated gene signatures but is limited by the invasiveness of bronchoscopy. Based on...

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.

Asthma is a heterogeneous condition and affected individuals show variable responses to available medications. An unmet need exists for add-on...

Key factors for implementing inhaler regimen switches in respiratory diseases: international expert consensus generated using a modified nominal group technique (NGT).

To develop international expert consensus statements on when and how to implement inhaler switches for patients with asthma or chronic obstructive...

Small Airways Dysfunction and Remission in Adults With Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study.

Asthma remission is a feasible treatment goal. However, remission definitions vary, and predictive biomarkers remain underexplored.

Nasal gene expression shows a distinct signature in type 2-high asthma but not in type 2-low disease.

Type 2 (T2)-low asthma is defined by low levels of T2 inflammation and is associated with resistance to inhaled corticosteroids. Its molecular...